Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Study sponsor: Lakefront Biotherapeutics NV · LKFT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2039-07Estimated
Enrollment · participants546Estimated
Source updated2026-07-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.